SP600125: Difference between revisions

From XenWiki
Jump to navigation Jump to search
imported>Kevin
Created page with "==Description== MAPK/JNK inhibitor. A novel and selective inhibitor of c-Jun N-terminal kinase (JNK) SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP t..."
 
imported>Kevin
Line 2: Line 2:
MAPK/JNK inhibitor.
MAPK/JNK inhibitor.


A novel and selective inhibitor of c-Jun N-terminal kinase (JNK)
"A novel and selective inhibitor of c-Jun N-terminal kinase (JNK)
SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. It prevents the activation of inflammatory genes such as COX-2, IL-2 IFN-γ and TNF-α.8,9 It prevents the activation of JNK after brain ischemia and may be effective in treatment of ischemic stroke.10
SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. It prevents the activation of inflammatory genes such as COX-2, IL-2 IFN-γ and TNF-α.8,9 It prevents the activation of JNK after brain ischemia and may be effective in treatment of ischemic stroke.10"
*Sigma Description
*-Sigma Product Description


[[File:SP600125.png|frame|right|SP600125 structure, photo from Sigma-Aldrich]]
[[File:SP600125.png|frame|right|SP600125 structure, photo from Sigma-Aldrich]]

Revision as of 06:42, 1 June 2015

Description

MAPK/JNK inhibitor.

"A novel and selective inhibitor of c-Jun N-terminal kinase (JNK) SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. It prevents the activation of inflammatory genes such as COX-2, IL-2 IFN-γ and TNF-α.8,9 It prevents the activation of JNK after brain ischemia and may be effective in treatment of ischemic stroke.10"

  • -Sigma Product Description
SP600125 structure, photo from Sigma-Aldrich

Genes Affected

mapk8 mapk1

Suppliers

Usage Notes

References


>28 Xenbase articles contain a reference to SP600125 according to textpresso